Conduit Pharmaceuticals Inc. (CDT)
NASDAQ: CDT · Real-Time Price · USD
3.480
-0.630 (-15.33%)
At close: May 23, 2025, 4:00 PM
3.570
+0.090 (2.59%)
After-hours: May 23, 2025, 7:29 PM EDT
Conduit Pharmaceuticals Employees
Conduit Pharmaceuticals had 6 employees as of December 31, 2024. The number of employees decreased by 1 or -14.29% compared to the previous year.
Employees
6
Change (1Y)
-1
Growth (1Y)
-14.29%
Revenue / Employee
n/a
Profits / Employee
-$3,232,667
Market Cap
2.78M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6 | -1 | -14.29% |
| Dec 31, 2023 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
CDT News
- 3 days ago - Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market - GlobeNewsWire
- 4 days ago - Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance - GlobeNewsWire
- 9 days ago - Conduit Pharmaceuticals Inc. Announces Reverse Stock Split - GlobeNewsWire
- 16 days ago - Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases - GlobeNewsWire
- 17 days ago - Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset - GlobeNewsWire
- 5 weeks ago - Conduit Pharmaceuticals Announces Leadership Changes - GlobeNewsWire
- 6 weeks ago - Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects - GlobeNewsWire
- 7 weeks ago - Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases - GlobeNewsWire